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’ INTRODUCTION
Dynamic nuclear polarization (DNP) of 13C-labeled cell
substrates enhances their sensitivity to detection in vivo by over
10,000-fold. DNP has shown great promise for metabolic
imaging of cancer in preclinical studies, with a wide range of
substrates now available1 including hyperpolarized [1-13C]-pyr-
uvate, which enables early detection of tumor response to drug
treatment2,3 and noninvasive assessment of tumor grade;4
[2-13C]-fructose, phosphorylation of which is inﬂuenced by both
glycolytic and pentose phosphate pathway activity;5 [1,4-13C2]-
fumarate, which is emerging as a marker of cell death following
chemotherapy;2,6 and [13C]-bicarbonate, which allows assess-
ment of tumor pH.7 Although these hyperpolarized substrates
probe a wide range of biological processes, there are currently no
hyperpolarized substrates that report directly on tumor redox
status. Rapid cancer cell proliferation promotes intracellular
accumulation of reducing equivalents such as glutathione and
NADPH8 to counteract the eﬀects of reactive oxygen species
(ROS) and to maintain redox balance.9 The ability of certain
cancer cells to maintain a highly reduced intracellular environ-
ment is strongly correlated with aggressiveness and drug
resistance.10,11 Noninvasive imaging of tumor redox status may
therefore indicate prognosis and give an early readout of treat-
ment response. Recently, 13C-benzoylformic acid (BFA) was
shown to report speciﬁcally on hydrogen peroxide concentration
in vitro, but its application in vivo is likely to be limited by a lack
of sensitivity.12 To be used in vivo, 13C-labeled DNP substrates
must exhibit long spinlattice relaxation times (T1's), be rapidly
transported (or react in the extracellular space), and produce an
observable chemical shift change between the injected substrate
and its product, to allow spectroscopic imaging of both metabo-
lites. The chemical and biological properties of vitamin Cmake it
a prime candidate for in vivo detection of redox status: the C1
carbonyl group has a long T1, its oxidation produces a chemical
shift diﬀerence of ∼5 ppm, the oxidized form is transported
rapidly by the samemembrane transporters utilized by glucose,13
and its redox state is coupled to two primary cellular antioxidants,
glutathione and NADPH.14
The reduced form of vitamin C, ascorbic acid (AA), is an
essential water-soluble antioxidant and cofactor of numerous
enzymes involved in biosynthetic reactions.14 AA is reversibly
oxidized (Figure 1), forming the stable ascorbic free radical
(AFR) intermediate with the loss of one electron or dehydroas-
corbic acid (DHA) with the loss of two electrons. AFR decays by
disproportionation to AA and DHA, whereas DHA sponta-
neously hydrolyses under physiological conditions, with the open-
ing of the lactone ring to form diketogulonic acid (DKG).15
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ABSTRACT: Dynamic nuclear polarization (DNP) of 13C-labeled
metabolic substrates in vitro and their subsequent intravenous admin-
istration allow both the location of the hyperpolarized substrate and the
dynamics of its subsequent conversion into other metabolic products to
be detected in vivo. We report here the hyperpolarization of [1-13C]-
ascorbic acid (AA) and [1-13C]-dehydroascorbic acid (DHA), the
reduced and oxidized forms of vitamin C, respectively, and evaluate
their performance as probes of tumor redox state. Solution-state
polarization of 10.5 ( 1.3% was achieved for both forms at pH 3.2, whereas at pH 7.0, [1-13C]-AA retained polarization of 5.1
( 0.6% and [1-13C]-DHA retained 8.2( 1.1%. The spinlattice relaxation times (T1's) for these labeled nuclei are long at 9.4 T:
15.9 ( 0.7 s for AA and 20.5 ( 0.9 s for DHA. Extracellular oxidation of [1-13C]-AA and intracellular reduction of [1-13C]-DHA
were observed in suspensions ofmurine lymphoma cells. The spontaneous reaction of DHAwith the cellular antioxidant glutathione
was monitored in vitro and was approximately 100-fold lower than the rate observed in cell suspensions, indicating enzymatic
involvement in the intracellular reduction. [1-13C]-DHA reduction was also detected in lymphoma tumors in vivo. In contrast, no
detectable oxidation of [1-13C]-AA was measured in the same tumors, consistent with the notion that tumors maintain a reduced
microenvironment. This study demonstrates that hyperpolarized 13C-labeled vitamin C could be used as a noninvasive biomarker of
redox status in vivo, which has the potential to translate to the clinic.
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While epithelial cells of the intestine, liver, and kidney can
transport AA directly through sodium-dependent vitamin C
transporters (SVCT1, 216), the primary means by which most
tissues acquire vitamin C is through transport of DHA, which
forms a stable bicyclic hydrated hemiacetal structure in aqueous
solution.17,18 Studies in tumor cell lines have found that they
either lack the capacity to transport AA, or if they do have
the capability, the rate of uptake of DHA is at least an order
of magnitude faster.19 DHA is taken up by the glucose
transporters13,20 GLUT1 (Km = 1.1 mM) and GLUT3 (Km =
1.7 mM) (Figure 2), which display a similar aﬃnity for both
glucose and DHA and are overexpressed in most tumors
compared to normal tissue.21 This phenomenon is widely
exploited in detection and staging of tumors by [18F]-ﬂuoro-
deoxyglucose positron emission tomography (FDG PET).9,22
Once inside the cell, DHA must be reduced rapidly to avoid
hydrolysis23 and maintain antiscorbutic activity. This can occur
spontaneously or enzymatically, by reaction with glutathione
(GSH) or GSH-dependent enzymes (Km = 2.2 mM) and
through NADPH-dependent reactions, primarily involving the
enzyme thioredoxin reductase (Km = 0.7 mM).
14 Glutathione-
dependent enzymes include the thiol-disulﬁde oxidoreductases,
glutaredoxin and protein disulﬁde isomerase, while the predomi-
nant NADPH-dependent enzyme is the selenoprotein, thiore-
doxin reductase (Figure 1). In both cases, rapid intracellular
reduction of DHA will maintain a favorable gradient for
transport.19
The upregulation of the glutathione and thioredoxin antiox-
idant systems in tumors has been implicated in both chemore-
sistance and increased metastatic potential.10,2426 While the
dominant mechanism of DHA reduction remains unresolved in
cancer cells, NADPH provides the reducing power for both of
these systems, and therefore the rate of intracellular reduction of
DHA is determined ultimately by the availability of NADPH and,
in turn, pentose phosphate pathway activity, reﬂecting oxidative
stress.27,28 Furthermore, oxidative stress is associated with almost
all major diseases and in addition to cancer has been implicated in
numerous neurodegenerative and cardiovascular conditions.11
Oxidative stress has been assessed in the clinic, at a systemic level,
from measurements of plasma ubiquinol and ubiquinone29 and
from measurements of serum antioxidants and the presence of
oxidized protein and lipid.30 Although imaging regions of
oxidative stress in tissues should provide a more sensitive readout
in a range of diseases, this has been limited to date by the lack of
available probes and there are currently no methods available to
image the spatial distribution of redox state in the clinic. Imaging
measurements of nitroxide reduction, either directly using EPR
imaging31,32 or indirectly from T1-weighted MRI measurements,
have shown great promise in preclinical studies,33 but these
techniques have yet to translate to the clinic. The rapid inter-
conversion of the reduced and oxidized forms of vitamin C
in vivo makes them ideal candidates for hyperpolarized redox
imaging, with AA primarily an extracellular probe and DHA an
intracellular redox probe. The goal of this study was to evaluate
the performance of [1-13C]-AA and [1-13C]-DHA as hyperpo-
larized imaging probes using cancer models in vitro and in vivo.
’METHODS
Hyperpolarization of [1-13C]-Ascorbic Acid and [1-13C]-
Dehydroascorbic Acid. A 1.5 M solution of [1-13C]-AA (Omicron
Figure 2. Mechanism of vitamin C transport, in both reduced (AA) and
oxidized (DHA) forms, by sodium-dependent vitamin C transporters 1
and 2 (SVCT 1, 2) and glucose transporters (primarily GLUT1, 3 and
also GLUT 4), respectively. This is dominated in cancer cells by GLUT1
transport of DHA, with SVCTs either not expressed or having low
activity due to the acidic extracellular pH in tumors.19,21
Figure 1. Primary intracellular oxidation, reduction, and degradation pathways for vitamin C. Enzymes involved in GSH- and NADPH-dependent
reduction of dehydroascorbic acid (DHA) are highlighted, with the primary cytosolic enzymes in bold.14 Abbreviations: AA, ascorbic acid; AFR,
ascorbate free radical (also known as semidehydroascorbic acid); DHA, dehydroascorbic acid; DKG, diketogulonic acid; GSH, reduced glutathione;
GSSG, oxidized glutathione.
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Biochemicals, Inc., South Bend, IN) in 60:40 H2O/glycerol or a 1.8 M
solution of [1-13C]-DHA (Supporting Information) in DMSO-d6,
containing 14.8 mM trityl radical (OX063; GE Healthcare, Amersham,
UK) and 1.4 mM of gadolinium chelate (Dotarem; Guerbet, Roissy,
France), were polarized as described previously.3 Briefly, the sample was
rapidly cooled under liquid helium in a GE Healthcare DNP prototype
hyperpolarizer at a pressure of ∼1 mBar to ∼1.2 K. Polarization of the
electron spins on the trityl radical were transferred to the 13C label using
microwave irradiation at 94.010 GHz (100 mW) over 1 and 1.5 h for
[1-13C]-AA and [1-13C]-DHA, respectively. The frozen samples were
dissolved in 5 mL of water (pH ∼3.2). For in vivo administration,
samples were neutralized by addition of a further 1 mL of phosphate
buffer (200 mM; pH 7.8) containing EDTA (1.8 mM) and NaCl
(400 mM) to yield a final pH and osmolality in the physiological range
(pH 7.07.2; >310 mOsm/kg). This procedure prevented significant
sample degradation and loss of polarization.
Hyperpolarized 13C NMR Spectroscopy in Vitro at 9.4 T.
NMR studies of reaction kinetics in vitro were performed on a 9.4 T
vertical wide-bore spectrometer (100 MHz 13C, Oxford Instruments,
Abingdon, U.K.) using a 10 mm 13C broadband probe (Varian NMR
Instruments, Palo Alto, CA) and temperature-controlled at 37 C.
Samples of the [1-13C]-AA (46 μL; 14 mM on dissolution) or
[1-13C]-DHA (39 μL; 14 mM on dissolution) preparations were
hyperpolarized, and measurements of the percentage polarization for
both substrates were made with a liquid-state polarimeter (Amersham
Health R & D, Malm€o, Sweden) approximately 8 s after the dissolution,
at both pH 3.2 and 7.0. For [1-13C]-AA, the reading was confirmed by
acquisition of 25 pulse and acquire 13C NMR spectra at approximately
10 s post dissolution (number of transients (nt) = 1, 32 kHz spectral
window, 5 s pulse repetition time (TR), 65 flip angle pulse, total
acquisition time of 105 s) followed by acquisition of spectra at thermal
equilibrium from the same solution (nt = 16, 32 kHz spectral window,
TR = 200 s, 65 flip angle pulse, total acquisition time of 50 min). The
polarization was calculated by comparing the first hyperpolarized
spectrum with the spectrum at thermal equilibrium, correcting for
differences in the number of transients. This measurement could not
be performed with [1-13C]-DHA due to the rapid hydrolysis of the
sample, with a half-life of approximately 10 min at neutral pH.23 The T1
of the hyperpolarized 13C label was determined in a separate experiment
at pH 7.0 using 180 spectra acquired with an 8 flip angle pulse (nt = 1,
16 kHz spectral window, TR = 1 s, total acquisition time of 3 min) and
fitting the decay of the integrated peak intensity to eq 1:
S ¼ S0 exp nTRT1
 
cosðRÞn ð1Þ
where S0 is the initial integrated peak intensity, TR is the repetition time
in seconds, T1 is the spinlattice relaxation time in seconds, R is the flip
angle, and n is the number of preceding RF pulses.
To determine the reaction kinetics of [1-13C]-DHA with glutathione
(GSH), hyperpolarized [1-13C]-DHA (2mL) was injected into a 10mm
NMR tube containing a solution of GSH (2 mL, 100 mM) in phosphate
buﬀer (100 mM, pH 7.4) with EDTA (0.3 mM), to yield ﬁnal
concentrations of 5 mM [1-13C]-DHA and 50 mM GSH at pH 7.3;
240 spectra were then recorded using an 8 pulse (nt = 1, 24 kHz spectral
window, TR = 1 s, total acquisition time of 4 min). This was repeated for
ﬁnal GSH concentrations of 1, 5, 10, and 25mM.The rate of [1-13C]-AA
production, kDHA, was determined by ﬁtting the peak integrals to the
modiﬁed Bloch equations for two-site exchange2,3,6 with the back-ﬂux of
the reaction, kAA, set to zero. The relationship between the forward ﬂux
([DHA]  kDHA) and the rate of production of AA determined
spectrophotometrically (see Supporting Information) was established
using linear regression in Prism (Graphpad, San Diego, CA).
For spectroscopic studies of vitamin C turnover in cancer cells,
EL-4 murine lymphoma cells were grown in RPMI 1640 medium
supplemented with 10% fetal calf serum and 2 mM L-glutamine
(culture media from Invitrogen). Cell number and viability were
assessed using trypan blue dye staining. Cells (1 108) were suspended
in RPMI 1640 medium (2 mL) in a 10-mm NMR tube. For the
experiments with AA the dissolution was performed within 2.5 min of
resuspension of the cells to allow for generation of extracellular ROS and
for the DHA experiments within 1.5 min in order to minimize ROS
generation. The hyperpolarized substrate under study (2 mL, 14 mM)
was injected into the cell suspension at approximately 10 s post
dissolution. RPMI 1640 medium was found to be suﬃcient to buﬀer
the hyperpolarized sample dissolved in water to pH 7.0. Spectra (180)
were recorded using an 8 ﬂip angle pulse (nt = 1, 16 kHz spectral
window, TR = 0.5 s, total acquisition time of 3 min) starting at the
beginning of hyperpolarized substrate injection.
Hyperpolarized 13C Spectroscopy (MRS) in Vivo at 9.4 T.
For experiments in vivo, a 24-mm diameter surface coil tuned to 13C
(100 MHz) was used in combination with a quadrature 1H-tuned
volume coil (Varian NMR Instruments, Palo Alto, CA), as described
previously.2 Transverse 1H spinecho images were acquired to localize
the tumor and plan voxels for MRS (TR = 500 ms, TE = 10 ms, field-of-
view = 35  35 mm2 in a data matrix of 256  256; 21 slices of 2 mm
thickness). After administration of [1-13C]-AA or [1-13C]-DHA
(0.2 mL; 30 mM, 1.1 mg/kg), 200 spectra were acquired from a 6
mm tumor slice using a nominal flip angle of 10 (every fifth spectrum
was non-slice selective), with TR = 1 and 0.25 s for AA and DHA,
respectively. The T1 of each substrate was estimated by fitting the peak
integrals of the injected substrate in the non-slice selective spectra to
eq 1. Over 250 mg/kg intravenous AA, a 250-fold excess compared to
the dose here, is administered in pharmacological studies without side
effects.34 High dose infusions of DHA (up to 60 mg/kg) can cause
elevated blood pressure and CNS responses in healthy rats,35 but this
level is 60-fold in excess of that used in this study, and adverse effects on
blood pressure were not observed here.
’RESULTS AND DISCUSSION
The measured polarizations and T1's for the labeled C1
position in both ascorbic acid and dehydroascorbic acid at
9.4 T are given in Table 1. [1-13C]-DHA and [1-13C]-AA exhibit
a similar level of polarization at pH 3.2, but at neutral pH,
[1-13C]-DHA retains a degree of polarization signiﬁcantly higher
than that of [1-13C]-AA (p = 0.05; n = 6). The loss of [1-13C]-AA
polarization at physiological pH (5.1 ( 0.6% vs 10.5 ( 1.3% at
pH 3.2, p = 0.008; n = 6) can be attributed to the fact that the
hydroxyl group at the C3 position has a pKa of 4.2 and so is
completely dissociated at pH 7.0. The polarization of [1-13C]-
DHA is also slightly lower at neutral pH (p = 0.12; n = 8), relating
in part to hydrolysis of the sample prior to measurement.
The polarization values reported here are lower than those
commonly reported for [1-13C]-pyruvate, which are in the range
of 2035%, but are within the range of other molecules imaged
in vivo including [13C]-bicarbonate and [2-13C]-fructose.
As expected, the C1 position in [1-
13C]-DHA displays a longer
T1 than that of [1-
13C]-AA in vitro (p = 0.003; n = 3), but
there was no signiﬁcant diﬀerence in the estimated T1 values of
the two species in vivo, which are in agreement with those
measured in erythrocyte suspensions36 and of a similar order to
those found for hyperpolarized [13C]-bicarbonate and [2-13C]-
fructose.
The intracellular reduction of DHA depends on NADPH,
both through glutathione-dependent reactions, which require
NADPH to replenish the reduced glutathione pool, and directly
through NADPH-dependent reactions. The observed reduction
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of hyperpolarized [1-13C]-DHA in vitro and in vivo is likely to
depend in large part on the reaction with reduced glutathione,14
proceeding via both spontaneous and enzymatic reactions. The
spontaneous reaction of DHA with glutathione is thermodyna-
mically favorable at physiological pH (Keq = 2.5  105 M1 at
pH 7) but proceeds slowly at endogenous concentrations of
DHA (micromolar) and glutathione (few millimolar).10,11 There-
fore, we sought to establish the rate at which higher concentrations
of [1-13C]-DHA react spontaneously with glutathione to deter-
minewhether this could contribute to the [1-13C]-DHA reduction
observed in cancer cell suspensions in vitro and tumor xenografts
in vivo. The reaction of [1-13C]-DHA with glutathione yielded
[1-13C]-AA at 179 ppm (Figure 3a) immediately following
addition of [1-13C]-DHA to the glutathione-containing buﬀer.
The [1-13C]-AA signal reached maximal intensity within 716 s
depending on the concentration of glutathione (Figure 3b). The
ratio of the peak integrals of AA and DHA in the spectrum
containing themaximumAA signal was calculated and found to be
linear with both glutathione concentration and the rate of AA
production (data not shown). The rate of [1-13C]-AA production
was established bymultiplying the amount of DHA (micromoles)
with the apparent rate constant of the reaction kDHA (s
1), and
this showed a linear correlation with the rate of AA production
measured spectrophotometrically under equivalent experimental
conditions (Figure 3c, see also Supporting Information; y = (1.00
( 0.04)x; r2 = 0.992). The second order rate constant for the
reaction derived from the spectrophotometric data, 0.34 ( 0.01
M1 s1, was in excellent agreement with previously reported
data.37
Oxidation of [1-13C]-AA to [1-13C]-DHA was observed at a
rate of 327 ( 41 μmol/s ([AA] x kAA) in suspensions of EL4
lymphoma cells at 2.5 min after resuspension of the cells in fresh
RPMI medium (Figure 4b, e). No oxidation was observed when
[1-13C]-AAwas added to either RPMImedium alone (Figure 4a)
or to cells at 1 min after resuspension, although a low level
became apparent at 2 min after cell resuspension (data not
shown). Cell culture imposes a state of oxidative stress on
cells, with antioxidants provided primarily in supplemented
serum.38,39 Cancer cells in vitro constitutively release hydrogen
peroxide,38 which readily penetrates the cell membrane and is
relatively stable in most culture media compared to reactive
oxygen species.40 Following resuspension, cells are not only
deprived of serum antioxidants, leading to an increased rate of
intracellular superoxide generation38 and in turn, a higher release
of hydrogen peroxide, but will also rapidly deplete the medium of
oxygen and nutrients, leading to an acutely hypoxic state.
Furthermore, the pharmacological eﬀects of high concentrations
of AA (>0.3 mM) have been attributed to the generation of
hydrogen peroxide through the reduction of catalytic metals such
as Cu(II), which are present in cell culture media, by AA.41 AA is
known to be oxidized by hydrogen peroxide,42 so the observation
of [1-13C]-AA oxidation at increasing time after resuspension is
likely due to accumulation of hydrogen peroxide and is consistent
with the notion that this is an extracellular reaction.
Conversely, the reduction of [1-13C]-DHA (Figure 4d, f) was
observed only at early time points (<1 min) after cell resuspen-
sion and returned to baseline by 2.5 min. Reduction of [1-13C]-
DHA was observed in RPMI medium alone, which contains
0.0033 mM glutathione.43 The medium also contains other
factors that have been documented to both reduce and hydrolyze
DHA, including sodium bicarbonate44 and cystine,45 as well as
11 mM D-glucose, which may competitively inhibit DHA trans-
port. The ﬁnal concentrations of glutathione, cystine, bicarbo-
nate and glucose in these experiments were 0.0017, 0.104, 11.9,
and 5.5 mM respectively, with a ﬁnal concentration of 7 mM
[1-13C]-DHA. Based on the measurements made above, the rate
of [1-13C]-AA production due to spontaneous reaction with the
glutathione in RPMI would be 0.15 nmol/s. The rates observed
in RPMI medium and EL4 lymphoma cell suspensions were
99( 6 nmol/s (n= 2) and 223( 18 nmol/s (n= 3), respectively.
The contribution of the spontaneous reaction with glutathione
may therefore be assumed to be negligible in EL4 cell suspen-
sions, indicating that other constituents of RPMI contribute to
the reduction of DHA in vitro and that a further reaction,
enzymatic or otherwise, occurs within EL4 cells. The shorter
Table 1. T1 Relaxation TimesMeasured in Vitro and in Vivo at 9.4 T and Percent PolarizationMeasured at Acidic and Neutral pH
Approximately 8 s Post Dissolution
polarization (%) T1 (s)
vitamin C form pH 3.2 pH 7.0 in vitro (pH 7.0) in vivo
[1-13C]-ascorbic acid 10.5( 1.3 5.1( 0.6 15.9( 0.7 8.6( 0.7
[1-13C]-dehydroascorbic acid 10.7( 1.3 8.2( 1.1 20.5( 0.9 11.9( 0.1
Figure 3. (a) 13C NMR spectra of hyperpolarized [1-13C]-DHA
(175 ppm) at the peak of [1-13C]-AA (179 ppm) production following
reaction of 5 mM [1-13C]-DHA with 1, 5, 10, 25, and 50 mM
glutathione. Peaks at 173.5 and 175.4 ppm are from diketogulonic acid
and an unknown product, respectively. (b) Time course of [1-13C]-AA
peak intensity at various glutathione concentrations, normalized to the
maximum [1-13C]-DHA intensity. (c) Correlation of the rate of [1-13C]-
AA production, [DHA]  kDHA, with the rate of AA production
measured spectrophotometrically at equivalent concentrations of
DHA and glutathione.
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T1 of DHA in cell suspensions compared to RPMI medium,
20.8( 0.7 s (n = 5) versus 17.9( 1.7 s (n = 3), may be due to the
intracellular transport of this substrate.
The in vivo metabolism of [1-13C]-AA and [1-13C]-DHA is
demonstrated in Figure 5. Intravenous administration of 30 mM
[1-13C]-AA yielded no observable [1-13C]-DHA resonance in
EL4 lymphoma tumors (Figure 5a; n = 4), whereas administra-
tion of 30 mM [1-13C]-DHA resulted in readily detectable
production of [1-13C]-AA (Figure 5b; n = 4) and hydrolysis to
[1-13C]-DKG. The apparent rate constant for the in vivo reduc-
tion of [1-13C]-DHAwas kDHA = 0.020( 0.004 s1. The ratio of
the peak integrals of [1-13C]-AA and [1-13C]-DHA calculated
within the ﬁrst 1 s of data acquisition (summation of the ﬁrst 4
FIDs) was 0.35 ( 0.08, with an average signal-to-noise ratio for
the [1-13C]-DHA peak of 67 ( 20 over the same period. By
comparison, the peak ratio in the non-slice selective spectrum
taken at 1.25 s was 0.17 ( 0.03, indicating that a signiﬁcant
portion of the overall reduction of [1-13C]-DHA occurs in the
tumor. The EL4 tumor concentration of glutathione was deter-
mined by the method of Tietze et al.46 to be 1.18( 0.03 μmol/g
wet wt, corresponding to approximately 1.2 mM in the tumor
tissue.46,47 Given the results in Figure 3, at this concentration the
spontaneous reaction of DHA with glutathione would be ex-
pected to proceed at a rate of only 0.0004 s1 and produce a
maximum relative signal intensity of 0.013 for [1-13C]-AA. These
data provide further evidence that an enzymatic reaction is
required to account for both the rate and level of [1-13C]-AA
produced in EL4 cells. The lack of observable oxidation of
[1-13C]-AA in vivo, despite the high level seen in cell suspen-
sions, together with the rapid reduction of [1-13C]-DHA,
indicate that upregulation of antioxidant systems allows tumors
to maintain a reduced microenvironment.48
’CONCLUSIONS
In this study, we have demonstrated hyperpolarization of
[1-13C]-ascorbic acid and [1-13C]-dehydroascorbic acid, the
reduced and oxidized forms of vitamin C, to relatively high
levels. Both compounds have been administered previously in
high doses in clinical studies with little or no observed toxicity
and were shown here to exhibit suﬃciently long T1's to allow
observation of their signals in vitro and in vivo. The extracellular
pool of [1-13C]-AA was oxidized rapidly in hypoxic EL4 cell
suspensions but not in vivo, as might be expected given that
tumors maintain a reduced microenvironment. [1-13C]-AA may
ﬁnd application in diseases that lead to a high level of extracellular
ROS, for example, for imaging of inﬂammation, where high levels
of superoxide and hydrogen peroxide are generated by immune
cells.38 Rapid intracellular reduction of [1-13C]-DHA was ob-
served, both in EL4 tumor cell suspensions in vitro and in EL4
tumor xenografts in vivo. The rate of reduction could not be
accounted for by the direct reaction with glutathione. [1-13C]-
DHA is transported by the glucose transporters GLUT1 and 3,
which are often overexpressed in tumor cells but are also
abundant at the bloodbrain barrier. Given the association of
oxidative stress with neurodegenerative diseases and the avid
utilization of vitamin C in the brain,49 [1-13C]-DHAmay provide
a hyperpolarized probe for clinical imaging of redox status in vivo
not only in cancer but in a wide range of pathologies and could
Figure 4. Oxidation of [1-13C]-AA (a, b, e) and reduction of [1-13C]-DHA (c, d, f) in EL4 lymphoma cell suspensions. Hyperpolarized substrates were
added to either RPMI medium alone (a, c) or a suspension of 108 EL4 lymphoma cells in RPMI medium. (b) Spectrum obtained at 2.5 min post cell
resuspension and (d) at 1.5 min post cell resuspension. Only every fourth spectrum is displayed in the interests of clarity (e, f; time course over 46 s).
Peaks at 172.6 and 176.4 ppm are from diketogulonic acid and the C3 carbon of AA,50 respectively.
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enable resolution of the role of vitamin C in both physiological
and pharmacological situations.
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bS Supporting Information. Method of oxidation of
[1-13C]-AA to [1-13C]-DHA, as well as the UV spectrophoto-
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available free of charge via the Internet at http://pubs.acs.org.
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